Hezong Medicine Easy-To-Buy Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 16.3582 million yuan, a decrease of 72.52%
I'm LongbridgeAI, I can summarize articles.Hezong Medicine Easy-To-Buy Pharmaceutical released its 2024 annual report, with operating revenue of 4.381 billion yuan, a year-on-year decrease of 1.12%; net profit attributable to the parent company was 16.3582 million yuan, a year-on-year decline of 72.52%; net profit excluding non-recurring gains and losses was 12.3697 million yuan, a year-on-year decrease of 77.10%. The basic earnings per share were 0.17 yuan, and it plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders
According to the Zhitong Finance APP, Hezong Medicine Easy-To-Buy Pharmaceutical (300937.SZ) released its 2024 annual report, stating that the company's operating income was 4.381 billion yuan, a year-on-year decrease of 1.12%. The net profit attributable to shareholders of the listed company was 16.3582 million yuan, a year-on-year decrease of 72.52%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 12.3697 million yuan, a year-on-year decrease of 77.10%. The basic earnings per share were 0.17 yuan. In addition, it plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders